2018-04-09
Hangzhou Tianlong Group launched China's first anti-hepatoma anti-sense nucleic acid drug CT102 (1.1) into the clinical stage
————
Recently, the anti-liver cancer type 1.1 new drug CT102 and its preparation (CT102 for injection) jointly developed by Tianlong Pharmaceuticals and the Academy of Military Medical Sciences of Hangzhou Tianlong Group have successfully obtained the SFDA clinical approval, and a clinical phase I trial is about to be launched to evaluate the use of the drug. Safety and effectiveness for the patient.
Read More